secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001193125-26-099404
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto rebrands as Damora Therapeutics (DMRA); $535M cash; DMR-001 IND mid-2026
--------------------------------------------------------------------------------

- Name changed from Galecto to Damora Therapeutics; trades on Nasdaq as DMRA from March 10, 2026.
- Preliminary cash and cash equivalents ~$535M as of Feb 28, 2026, including ~$316M from Feb 2026 public offering.
- DMR-001 (anti-mutCALR antibody) IND/CTA on track for mid-2026; proof-of-concept data expected mid-2027.
- DMR-002 IND/CTA planned for H2 2026; DMR-003 IND/CTA in 2027.
- Acquisition of privately held Damora closed Nov 2025 with ~$285M private investment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526099404/0001193125-26-099404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526099404/dmra-20260306.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-099404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer